Psoriasis

The well-being of your skin is not a superficial matter.

Psoriasis is a chronic autoimmune disease. In addition to scaly patches, particularly on the elbows, knees and scalp, it can also cause inflammation in joints, tendons, ligaments and nails. In acute cases, those affected may often feel stigmatised and excluded.

Using the most modern therapeutic methods in our practice, we can almost completely heal the symptoms of psoriasis, so that you feel comfortable in your skin again and can enjoy a normal everyday life.

Book an appointment online

Your questions.
Our answers.

How does psoriasis develop?

Psoriasis is a hereditary skin disease that can also be triggered by medication (e.g. beta blockers, calcium channel blockers) or infections (e.g. streptococcal angina). White blood cells trigger chronic inflammations and in psoriasis patients the skin becomes dry and scaly faster and more intensively.

Is psoriasis contagious and how can it be treated?

Psoriasis is not contagious. A complete cure is not possible for chronic diseases. Fortunately, the symptoms are often mild and do not require treatment. In more severe cases, however, we can offer very effective cream and immunosuppressive therapies with high response rates and an almost complete reduction in the symptoms.

Are there other diseases associated with psoriasis?

Psoriasis is a systemic disease and is often associated with coronary heart disease, obesity, diabetes mellitus, arterial hypertension and Crohn’s disease.

What triggers the disease?

Alcohol and smoking are known trigger factors for psoriasis.

What is biological therapy and how is it used?

These biotechnologically produced substances can intervene in the inflammatory cascade of psoriasis and block the action of anti-inflammatory molecules. As a result of a better understanding of the disease, new active ingredients are constantly being developed, enabling us to treat psoriasis more precisely.

In our practice we use the following preparations: the TNF alpha blocker Adalimumab (Humira), the IL 17 antibodies Brodalumab (Kyntheum), Secukinumab (Cosentyx) and Ixekizumab (Taltz), the IL12/23 antibodies Ustekinumab (Stelara), Guselkumab (Tremfya), Risankizumab (Skyrizi) and Tildrakizumab (Ilumetri) with action against IL 23 as well as the PDE-4 inhibitor Apremilast (Otezla).

Are there any other drugs that can be used?

Yes, very good long-term treatment results have been achieved with, for e.g., fumaric acid esters. Immunosuppressive therapy with methotrexate or Ciclosporin A is also an option.

Our range of services

We are here for you:
Heilwigstraße 33, 20249 Hamburg